Trials / Active Not Recruiting
Active Not RecruitingNCT06425302
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Golcadomide | Specified dose on specified days |
| DRUG | Rituximab | Specified dose on specified days |
| DRUG | Cyclophosphamide | Specified dose on specified days |
| DRUG | Doxorubicin | Specified dose on specified days |
| DRUG | Vincristine | Specified dose on specified days |
| DRUG | Prednisone | Specified dose on specified days |
| DRUG | Bendamustine | Specified dose on specified days |
Timeline
- Start date
- 2024-08-30
- Primary completion
- 2026-11-23
- Completion
- 2028-11-27
- First posted
- 2024-05-22
- Last updated
- 2026-01-08
Locations
56 sites across 13 countries: United States, Australia, Brazil, Canada, Chile, France, Germany, Italy, Poland, South Korea, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06425302. Inclusion in this directory is not an endorsement.